Project Details
Description
A Phase 1/ 2 Study of BAY 1895344 (Elimusertib, NSC#810486) in Pediatric Patients With Relapsed or Refractory Solid Tumors
| Status | Finished |
|---|---|
| Effective start/end date | 4/6/23 → 4/5/24 |
Funding
- PUBLIC HEALTH INSTITUTE
- BAYER HEALTHCARE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.